BACKGROUND: The purpose of this study was to assess the dosimetric and clinical feasibility of volumetric modulated arc based hypofractionated stereotactic radiotherapy (RapidArc) treatment for large acoustic schwannoma (AS>10 cc). MATERIALS AND METHODS: Ten AS patients were immobilized using BrainLab mask. They were subject to multimodality imaging (magnetic resonance and computed tomography) to contour target and organs at risk (brainstem and cochlea). Volumetric modulated arc therapy (VMAT) based stereotactic plans were optimized in Eclipse (V11) treatment planning system (TPS) using progressive resolution optimizer-III and final dose calculations were performed using analytical anisotropic algorithm with 1.5 mm grid resolution. All AS presented in this study were treated with VMAT based HSRT to a total dose of 25 Gy in 5 fractions (5 fractions/ week). VMAT plan contains 2-4 non-coplanar arcs. Treatment planning was performed to achieve at least 99% of PTV volume (D99) receives 100% of prescription dose (25 Gy), while dose to OAR's were kept below the tolerance limits. Dose-volume histograms (DVH) were analyzed to assess plan quality. Treatments were delivered using upgraded 6 MV un-flattened photon beam (FFF) from Clinac-iX machine. Extensive pretreatment quality assurance measurements were carried out to report on quality of delivery. Point dosimetry was performed using three different detectors, which includes CC13 ion-chamber, Exradin A14 ion-chamber and Exradin W1 plastic scintillator detector (PSD) which have measuring volume of 0.13 cm3, 0.009 cm3 and 0.002 cm3 respectively. RESULTS: Average PTV volume of AS was 11.3 cc (±4.8), and located in eloquent areas. VMAT plans provided complete PTV coverage with average conformity index of 1.06 (±0.05). OAR's dose were kept below tolerance limit recommend by American Association of Physicist in Medicine task group-101(brainstem V0.5 cc<23 Gy, cochlea maximum<25 Gy and Optic pathway<25 Gy). PSD resulted in superior dosimetric accuracy compared with other two detectors (p=0.021 for PSD.
BACKGROUND: The purpose of this study was to assess the dosimetric and clinical feasibility of volumetric modulated arc based hypofractionated stereotactic radiotherapy (RapidArc) treatment for large acoustic schwannoma (AS>10 cc). MATERIALS AND METHODS: Ten ASpatients were immobilized using BrainLab mask. They were subject to multimodality imaging (magnetic resonance and computed tomography) to contour target and organs at risk (brainstem and cochlea). Volumetric modulated arc therapy (VMAT) based stereotactic plans were optimized in Eclipse (V11) treatment planning system (TPS) using progressive resolution optimizer-III and final dose calculations were performed using analytical anisotropic algorithm with 1.5 mm grid resolution. All AS presented in this study were treated with VMAT based HSRT to a total dose of 25 Gy in 5 fractions (5 fractions/ week). VMAT plan contains 2-4 non-coplanar arcs. Treatment planning was performed to achieve at least 99% of PTV volume (D99) receives 100% of prescription dose (25 Gy), while dose to OAR's were kept below the tolerance limits. Dose-volume histograms (DVH) were analyzed to assess plan quality. Treatments were delivered using upgraded 6 MV un-flattened photon beam (FFF) from Clinac-iX machine. Extensive pretreatment quality assurance measurements were carried out to report on quality of delivery. Point dosimetry was performed using three different detectors, which includes CC13 ion-chamber, Exradin A14 ion-chamber and Exradin W1 plastic scintillator detector (PSD) which have measuring volume of 0.13 cm3, 0.009 cm3 and 0.002 cm3 respectively. RESULTS: Average PTV volume of AS was 11.3 cc (±4.8), and located in eloquent areas. VMAT plans provided complete PTV coverage with average conformity index of 1.06 (±0.05). OAR's dose were kept below tolerance limit recommend by American Association of Physicist in Medicine task group-101(brainstem V0.5 cc<23 Gy, cochlea maximum<25 Gy and Optic pathway<25 Gy). PSD resulted in superior dosimetric accuracy compared with other two detectors (p=0.021 for PSD.
Authors: Barbara Dobler; Tina Obermeier; Matthias G Hautmann; Amine Khemissi; Oliver Koelbl Journal: Radiat Oncol Date: 2017-07-05 Impact factor: 3.481